-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari Therapeutics prices $5.5 million unregistered private placement at $3.74 ADS

PUBT·05/21/2026 12:35:48
Listen to the news
Akari Therapeutics prices $5.5 million unregistered private placement at $3.74 ADS
  • Akari Therapeutics priced a private placement expected to raise about USD 5.5 million in gross proceeds.
  • Deal includes 1,470,588 unregistered ADSs, or prefunded warrants, priced at USD 3.74 per ADS.
  • Investors also agreed to receive unregistered Series H, Series I, Series J warrants, each exercisable for 1,470,588 ADSs at USD 3.74, subject to shareholder approval.
  • Funding is expected in three tranches with closings scheduled between May 27, 2026 and July 15, 2026.
  • Proceeds are earmarked for working capital, general corporate purposes, and advancing lead ADC candidate AKTX-101 toward a first-in-human Phase 1 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.